Search results for: HTA
Filter search results
HTA and Payment Mechanisms for New Drugs to Tackle AMR
1 September 2019
…to the value that they offer. At present, HTA methods for new antibiotics include benefits and costs associated with treating the immediate patient, while ‘public health effects’, such as preventing…
International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
5 January 2020
OHE presents an overview on the use of cost-effectiveness thresholds (CETs) in a number of selected countries in their decision-making process for health technology assessments (HTAs). In addition to the…
From the Antipodes to the Motherland: Reflections on HTA Decision Makers as Budget Takers and Budget Makers
14 December 2015, 12:00am
…an OHE Lunchtime Seminar on the topic of: HTA decision makers as budget takers and budget makers. The seminar will highlight that decision-making criteria employed by health technology assessment (HTA)…
Age, Utilities, and Self-Reported Health: Issues for HTA
28 June 2016
…to be used in Health Technology Assessment (HTA)? Is there a case for using utilities specific to age (or other relevant) sub-groups? To explore these questions, Patricia and colleagues used…
New Publication: Assessing Evidence and Access Associated with NICE HTA Decisions Categorised as “Recommended in Line with Clinical Practice”
6 January 2017
A new OHE Research Paper assesses the nature of evidence used to reach HTA decisions which NICE have classified as “Recommended in Line with Clinical Practice” between 2007 and mid-2016….
Age and Utilities: Issues for HTA
1 April 2017
…by age than TTO valuations. The authors conclude the paper with a thought-provoking debateby assessing the arguments for and against about a case for using age-specific utilities in HTA. Compared…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
In this OHE Seminar Briefing, Dr Steven Pearson, President of ICER, sets out ICER’s early experiences of using HTA to assess gene therapy in the US, setting out four primary…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
1 April 2019
…value assessment in delivering value for money. This is inconsistent with both existing WHA policy on HTA and the reality that more and more payers in WHO Member States are…
The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance
12 October 2022
…Market of the Future Look like? Related OHE research Neri, M., Hampson, G., Henshall, C. and Towse, A. (2019) HTA and Payment Mechanisms for New Drugs to Tackle AMR. OHE…